Navigation Links
New England Research Institutes (NERI) Announces Additional $45M NIH Grant to Support the Pediatric Heart Network
Date:10/25/2011

WATERTOWN, Mass., Oct. 25, 2011 /PRNewswire/ -- New England Research Institutes (NERI) today announced that it has received a $45 million grant from the National Institutes of Health (NIH) for the continuance of its work on the Pediatric Heart Network (PHN). PHN is a multi-center clinical research network started in 2001, supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, to study congenital and acquired heart diseases that occur in childhood. This grant provides five more years of funding to nine clinical centers and NERI as the data coordinating center, to conduct clinical research studies in children and young adults with heart defects and other heart diseases.

Congenital heart defects occur in approximately 40,000 infants in the US each year and are a major cause of infant death. The PHN was started by the NHLBI to find treatments for children with heart disease. Nine major studies have been conducted since 2001 at children's hospitals around the US and Canada with research teams that specialize in the care of patients with heart disease. The PHN also provides training in clinical research to new investigators, and is the clinical cornerstone of the NHLBI's comprehensive Bench to Bassinet (B2B) Program in pediatric cardiovascular translational research.

The B2B program was established to accelerate the translation of basic research findings into clinical studies and trials, and to provide clinical input on pressing needs for basic research. In addition to the PHN, the Program includes the Pediatric Cardiac Genomic Consortium (PCGC) conducting human genetic studies and the Cardiovascular Development Consortium (CvDC) focusing on basic research and animal models. NERI also serves as the coordinating center for the B2B program. The federal funding to NERI for its work on the PHN and on B2B totals $87 million over the next 5 years.

"Quality research conducted by the PHN over the last decade has led to better understanding of pediatric heart disease and how to treat it. Although there are many more questions to be answered, it is gratifying to see the PHN's mission of improving health outcomes in children begin to be realized, and a privilege for NERI to be a continuing partner in this important and exciting research," said Lynn Sleeper, Sc.D., Principal Investigator, Statistical and Clinical Science for the PHN Data Coordinating Center.

Sharon Tennstedt, Ph.D., Principal Investigator, Operations for the PHN Data Coordinating Center, and who also directs the B2B Coordinating Center, added, "NERI is very pleased to continue our role in the PHN. We look forward to more groundbreaking clinical studies, particularly as the Bench to Bassinet Program makes progress in identifying genetic causes of congenital heart defects."

For more information regarding PHN, please visit http://www.pediatricheartnetwork.com. For more information regarding B2B, please visit http://www.benchtobassinet.com.

About NERI

NERI is a privately held CRO that provides global, customized clinical trial solutions and registry services to pharmaceutical, biotechnology, biomaterial and medical device companies. NERI also has notable experience collaborating on federally funded research with organizations like the National Institutes of Health (NIH). Since its founding in 1986, NERI has earned widespread recognition for its scientific credibility, efficiency and expertise in conducting clinical trials in numerous therapeutic areas. For more information, visit http://www.neriscience.com .

Media Contact:

Sharon Tennstedt, Ph.D.
617-972-3362

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE New England Research Institutes
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
2. Biotech Group Warns Proposed Medicare Cuts Could Hurt Critical Sector of New England Economy
3. Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products
4. Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application
5. New England Biolabs Opens New Subsidiary Office in France
6. TEI Biosciences Wins SBANE 2011 New England Innovation Award
7. TEI Biosciences Chairman, President and CEO Yiannis Monovoukas Named Ernst & Young Entrepreneur Of The Year® 2011 New England Award Semifinalist
8. New England Cord Blood Bank: Umbilical Cord Tissue Banking
9. Stryker Knee and Hip Implants Demonstrate Lowest Revision Rates, According to the National Joint Registry for England and Wales
10. New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR
11. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth ... has joined the company as Chief Business Officer. Arianpour, a genomics pioneer and ... to market, was most recently Chief Commercial Officer of Pathway Genomics. He has ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business for ... multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The SI ... team,” said John Younger, founder of Accolo. “We are growing and his experience ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... announced receipt of a significant operating grant from 1Plus12 Corporation. The grant will ... commence pre-proposal activities as outlined on the organization's website http://www.ivsci.org , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):